Ethical and Equitable Data Sharing: Navigating the Benefits and Challenges

Nicki Tiffin SANBI, UWC ntiffin@sanbi.ac.za





Overview:

- Why should we do data sharing?
- When can we do data sharing?
- How can we do data sharing?
- How can we do benefit sharing?
- Introduction to the African Data and Biospecimen Exchange



Why should we do data sharing?


Participants make health research possible

• We ask them to invest time and energy:

Clinical appointments, filling in surveys, answering questions, follow up visits

• We ask them to take risks:

Data privacy, new treatments, health interventions, donate samples






Why should we do data sharing?

It's an ethical requirement to ensure benefits

- Use the data and specimens well
- Do as much research as possible, whilst respecting consents and ethical approvals
- Ethically share data and biospecimens in order to further research






Why should we do data sharing?

It's better for our research


- Larger sample size, better significance
- Validation datasets
- Generaliseable findings











Nicki Tiffin

When can we do data sharing?

When the law allows

- Health Act, patient confidentiality
- Protection of Personal Information Act
- In addition, various other Acts e.g. protection of minors, protection of people living with disability



When can we do data sharing?

In clinical research:

- Health data are collected at a health facility where a client has a consultation with a health provider.
- The primary reason that the data are collected is to ensure that the best possible care is provided to the client.
- The health care provider is bound by legislation about patient confidentiality, e.g. Health Act





The POPI Act in South Africa

The **Protection of Personal Information Act (POPI)**, South Africa (equivalent to GDPR in EU)

- Governs the use of personal information
- Synergises with the Health Act, upholds patient confidentiality
- Identifies "special" data, which include health data
- Governs international transfer of data
- Distinguishes identified data vs anonymised data
- Recognises informed consent







When can we do data sharing?

When the participant agrees

Informed consent processes

- Many debates about broad, tiered, dynamic consent
- Generally accepted broad consent is no longer sufficient
- Dynamic consent hard to do in low-resourced populations

Tiered consent increasingly being used Especially for health data: must adhere to POPI Act





Tamuhla, T. An e-consent framework for tiered informed consent for human genomic research in the global south, implemented as a REDCap template. *BMC Med Ethics* 23, 119 (2022). https://doi.org/10.1186/s12910-022-00860-2

DATABASE **Open Access** An e-consent framework for tiered informed consent for human genomic research in the global south, implemented as a REDCap template Tsaone Tamuhla¹, Nicki Tiffin^{1,2,3*} and Taryn Allie¹ Abstract Research involving human participants requires their consent, and it is common practice to capture consent infor-Primary consent for collecting biospecimens and health data for specific disease in current study Consent for access to medical records Consent for return of individual results

Consent for return of individual results that are actionable and/or treatable

Consent for return of individual results that are NOT actionable and/or treatable

Consent for inclusion of individual data in genetic summary data

Consent for use of genetic and health data for future studies on specific disease

Consent for use of genetic and health data for future studies on other health conditions or related health processes

Consent to re-contact for future studies

Consent for use of genetic and health data in international studies

Consent for use of genetic data in population origins and ancestry studies




When can we do data sharing?

When the participant can't be identified/re-identified

- Data are de-identified: names, ID numbers, folder numbers are removed
- Data are anonymised: de-identified and can't ever be re-linked to individuals
- Re-identification is a real risk for granular data (and genomic data):
- Use of data perturbation





Can data be re-identified?

A 37-year old lady with epilepsy attending a particular clinic on given dates.

A 12 year old, female, grade 6 learner who lives at 1 Green Street, Townsville.

Female baby born on 7 December 2021 at Mowbray Maternity clinic, recorded birthweight 3.4921 kg

• Do not manage de-identified data in the same way as truly anonymised data, because they can be re-identified.



Can data be re-identified?

Data perturbation

- Adding/deleting integers from dates
- Hide, round off or alter dates e.g. Year of birth
- Age scale e.g. days for neonates, weeks for newborns, months up to 2yrs, years thereafter
- 'time to' events in days from index event. e.g. Time in days to death after admission
- Round off numbers e.g. birthweights, VL or CD4 counts
- K ANONYMITY: For every identifying attribute a person has, there are at least k-1 others with the same value e.g. If at least ten people have a value of X₁=0.15, then k is 10



Can data be re-identified?

Trusted third party stewardship

- Independent, trusted third party joins datasets, then anonymises and perturbs before returning combined dataset
- Binding MoU/agreement for third party to delete all data

Data aggregation


• Rule of thumb: minimum 15 – 20 counts per aggregated data

Geographical data

 Geocoding can be identifying, use geographic regions, shapes, suburbs, and show aggregated data

NO DOTS ON MAPS








How can we do data sharing?

- Direct sharing
- Collaborative analysis
- Federated analysis
- Trusted Research Environments




Direct data sharing

- One party provides data to another party
- Unidirectional





Collaborative analysis, meta-analysis




- Data from two sources are combined
- Analysed as a single dataset: meta-analysis




Federated analysis

- Datasets are held separately by collaborating parties
- Data are independently analysed in the same way
- Findings are combined and reported jointly






Trusted research environment



- Analysis is run on a secure platform
- Actual data may not be visible
- Data may not be downloaded
- Only results of analysis may be downloaded



Data and biospecimen governance occurs across the data ecosystem





Data/biospecimen sharing in the global South

Inequitable power relationships

- Funders and collaborators from the global North
- Inequitable access to resources and infrastructure
- Helicopter science and "global health" agenda
- Unidirectional flow of samples and data to the global North
- Funding requirements mandate centralising samples and data in global North
- No benefit-sharing from secondary use
- Researchers can't access data or samples they collected





What about data and biospecimens from Africa?

Historical inequities, current barriers

• Reluctance to send data and biospecimens off-Continent

Legal limitations Risk of being scooped by better resourced labs No oversight of onward data use Lose access to own data/biospecimens

• Informed consent may not be sufficient

Legacy data without explicit consent Anonymised routine health data without informed consent



What about data and biospecimens from Africa?

Historical inequities, current barriers

• Data are too sensitive for open sharing

Genomic data Clinical trial data Personal health data

Research sustainability

No mechanisms for cost recovery Benefit sharing is not inculcated in resource sharing



The African Data and Biospecimen Exchange




- Online platform to connect resource generators and consumers
- Address barriers to sharing data and biospecimens from Africa
- Ensure equitable sharing agreements and benefit-sharing



The African Data and Biospecimen Exchange

- Catalogue datasets and biospecimens (resources) by metadata only
- Connect resource generators directly to consumers via online platform
- Provide resources to assist users with governance, sharing agreements





Currently under development – Estimated completion mid-2024

No need to send data and biospecimens away

- No centralisation
- Only metadata uploaded
- Resources remain with researcher/ institution
- Direct transfer, only after agreement reached
- Create listings of data or biospecimens you want to share

~	Create new listing	,
	Add a new post and we will alert those who showed intere	st in y
	shared tags.	Add to your listing Lorem lpsum dolor sit amet.
		Biospecimen
Title		Consent type
Н	ıman DNA	✓ Sample size
		Read more Remove from listing
Sta	tus	
Draf	t - Ready to publish	Specimen sollection data
		Sample count
Pr	review Publish	Collection institution Collection dates
		Sample type
_		Morphological code
\oslash	Essential details	Topographical code
	Please provide essential details for your post.	Read more Add to listing
$\dot{\diamond}$	Sample and provider details	Read more Add to listing
Ŷ	Details on the sample and provider	
		Sample proccessing data
\oslash	Participant(s) data details	Proccessing specimen category
Ī	Start collaborating with your team	Proccessing temperature conditions
		Sample type
\odot	Biospecimen and data set details	Sample container
T	Start collaborating with your team	 Fixation/ Sstabilization type/ Freezing mode
	Governance checklist	Sample quality methods
U	Share posts to your social accounts	⊘ Sample QC
		Read more Add to post
•••	Biospecimen	Storage data
••	Biospecimen	Storage date & time
	Consent type	Storage temperature
	Specific consent Unknown	Read more Add to listing
	General consent N/A	
		Distribution data
	Sample size	
	Aliquot no	Retrieval date Retrieval reason(s)
		Project destination
		O Delivery temperature
	cm ∽ Size, volume or mass	

No need to send data and biospecimens away

- No centralisation
- Only metadata uploaded
- Resources remain with researcher/ institution
- Direct transfer, only after agreement reached
- Create listings of data or biospecimens you want to share

 Create new listing Add a new post and we will alert those who show 	ed interest in y
shared tags.	Add to your listing Lorem ipsum dolor sit amet.
	Biospecimen
Title	O Consent type
Human DNA	Sample size
	Read more Remove from listing
Status	Specimen sollection data
Draft - Ready to publish	
Preview Publish	Sample count Collection institution
	Collection dates
	Sample type
• • • • • • • •	Morphological code
Essential details Please provide essential details for your post.	Topographical code
	Read more Add to listing
Sample and provider details	
Details on the sample and provider	Sample proccessing data
Participant(s) data details	 Proccessing specimen category
Start collaborating with your team	 Processing opcontain datagory Processing temperature conditions
	Sample type
 Biospecimen and data set details 	Sample container
Start collaborating with your team	Fixation/ Sstabilization type/ Freezin mode
Governance checklist	Sample quality methods
Share posts to your social accounts	⊘ Sample QC
	Read more Add to post
Biospecimen	Storage data
	Storage date & time
Consent type	Storage temperature
Specific consent 🗌 Unknown	Read more Add to listing
General consent N/A	
Sample size	Distribution data
	Retrieval date
Aliquot no	Retrieval reason(s)
	Project destination
cm ∽ Size, volume or mass	 Delivery temperature

Search metadata to find data and biospecimens

Popular Hun	nan Microbial Animal Other Eb	ola	×	Cancel Search	Keyword search	es
- <u>-</u>	Olivia Rhye • 20 Jan 2022 SLE, whole genome dataset for 80 South African	-	Filters Apply filters to table dat	a.	Review returned	
:@.	Lorem ipsum dolor sit amet, consectetur adipiscing elit ut aliguam, pur					u iistiiigs
	venenatis		Type Dataset		Start o	shat
	SARS 19 South Africa Dataset		Biospecimen		Start	
			Category			
= _	Kagee Jain• 20 Jan 2022		O Human			
:83.	M.tb cultures, Ghana Mycobacterium tuberculosis (M. tuberculosis) cultures. These M. tube	rculosis 🖂				
	isolated from patients in multiple locations Ghana					
	SARS 19 Ghana Dataset	\$		> Search > >	SLE, whole genome dataset for 80 South Africans	
			and the second s	—		
	Lame Moses • 20 Jan 2022	Φ		· –	nome dataset for 80 South Africans	Agreements Mes
-	WGS data, chronic kidney disease	Б	@0	livia Rhye, 12 January 2	2022	
+0D5*	Whole genome sequence data from participants with chronic kidney d					
	Bujumbura, Burundi.	6-3	Overview	Data set overvi	iew	Popular
	Chronic Kidney Disease Burundi Dataset		Specifications	A overview of the da	lata set.	Populai
						Gorilla beringei, DRC, DNA
	Theo Phapani • 20 Jan 2022		Governance	This detects	ontains Whole Genome Sequence for 80 participants	Olivia Rhye, Jan 13 2022
	Maternal outcomes, Tanzania		_		ica who have symptomatic systemic lupus	
:000.	This is an epidemiologic dataset from primary research on maternal or	tcomes	Research interests By clicking on a research	erythematosus	5.	Genetic modification study Olivia Rhye, Jan 13 2022
	women attending ante-natal clinics in Arusha, Tanzania	(comes	interest it will add the tag to			Human Rwanda (-85)-(-60)*C DNA
	Tanzania Dataset		your personalized research interest list.	About the data se	et	SARS 19, South Africa, Male, 20-24 year
			Human South Africa	DNA samples wer	re prepared from whole bloods donated by 80 study	Olivia Rhye, Jan 13 2022
			DNA		the age of 18 years who have symptomatic SLE.	Human Rwanda (-85)-(-60)°C DNA
-	Kagee Jain• 20 Jan 2022	8			e recruited at rheumatology and nephrology clinics at	
:·	M.tb cultures, Ghana	0		tertiary hospitals	in the Western Cape, South Africa.	
	Mycobacterium tuberculosis (M. tuberculosis) cultures. These M. tube isolated from patients in multiple locations Ghana	rculosis			a on disease severity is available for the participants. 59 of	Share this listing
	SARS 19 Ghana Dataset	, i i i i i i i i i i i i i i i i i i i			vomen DNA was sequenced on the Illumina platform to an 15x. Informed consent has been given by participants for	Invite colleagues to view this listing.
	SARS 19 Olialia Dataset				ples in secondary studies of SLE.	Share link
						abdex.co.za/listing/sle_whole
*: # :_	Lame Moses • 20 Jan 2022			Further studies		
:@?•	WGS data, chronic kidney disease Whole genome sequence data from participants with chronic kidney d	inanna ir			e genetic variants found in autoimmunity-associated genes ed in Brown et al. 2022, Journal name, PMID: XXXX.	
	whole genome sequence data from participants with chronic kidney d Bujumbura, Burundi.	15E05E		nas been publisht		
	Chronic Kidney Disease Burundi Dataset				boration is exploring novel aetiological variants in these	
				patients in a case	e-control study	
← Previous	1 2 3 8 9 10					

Search metadata to find data and biospecimens

Â	Popular Hur	nan Microbial Animal Other Ebola		X Cancel Search
ф Ъ		Olivia Rhye • 20 Jan 2022 SLE, whole genome dataset for 80 South Africans	л	Filters Apply filters to table data.
		Lorem ipsum dolor sit amet, consectetur adipiscing elit ut aliquam, purus venenatis SARS 19 South Africa Dataset	sit amet luctus	Type Dataset Biospecimen
		Kagee Jain∙ 20 Jan 2022		Category

Search filters Keyword searches Review returned listings Start chat

△ > Search > ... > SLE, whole genome dataset for 80 South Africans

SLE, whole genome dataset for 80 South Africans

@Olivia Rhye, 12 January 2022

Dr Eddie Lulamba



Data set overview

A overview of the data set.

This dataset contains Whole Genome Sequence for 80 participants from South Africa who have symptomatic systemic lupus erythematosus.

About the data set

ig to

rch

DNA samples were prepared from whole bloods donated by 80 study participants over the age of 18 years who have symptomatic SLE. Participants were recruited at rheumatology and nephrology clinics at tertiary hospitals in the Western Cape, South Africa.

Some clinical data on disease severity is available for the participants. 59 of the dataset are women DNA was sequenced on the lilumina platform to an average depth of 15x. Informed consent has been given by participants for use of these samples in secondary studies of SLE.

Further studies

An analysis of the genetic variants found in autoimmunity-associated genes has been published in Brown et al. 2022, Journal name, PMID: XXXX.

An ongoing collaboration is exploring novel aetiological variants in these patients in a case-control study

Popular

Д

Agreements

Message



SARS 19, South Africa, Male, 20-24 years old Olivia Rhye, Jan 13 2022 Human Rwanda (-85)-(-60)*C DNA

Share this listing


Invite colleagues to view this listing.

Share link

abdex.co.za/listing/sle_whole...

Chat function: discuss and agree sharing mode

**	÷					
Â	Templates					
Ľ M	You choose and customise a template that fits your agreement, following prompts and using agreement elements provided through the platform.					
\$	As you compile your agreement you can:					
φ	 Import information from profiles and listings on the platform Access resources and information to assist writing the agreement 					
60	Invite collaborators and institutional representatives to view, edit and/or sign the agreement					
	Direct transfer	Collaborative	Federated			
	transferred to the requestor and the data provider has no further involvement in the onward analysis.	undertake a joint analysis of the combined resource.	output from analysis of separate datasets or biospecimens.			
	Get started Preview	Preview	Preview			
	 Unidirectional share Review ethics approvals Agree permitted onward use Negociate benefit sharing Agree acknowledgements 	 Bi-directional sharing Review ethics approvals List participating researchers Identify researcher roles Agree analysis methodology Negotiate benefit sharing Define outputs 	 No sharing of data or biospecimens Agree analytical approach List participating researchers Identify researcher roles Define results to be combined Define IP and outputs Negotiate benefit sharing 			



Build a data- or biospecimen-sharing agreement

- Elements to create a customised data- or biospecimen-sharing agreement.
- Invite institutional representatives
- Negotiate benefit sharing
- Build a benefit sharing agreement

		Customise Sign Agreemen
÷		
	ata Sharing Agreement	
You	u are able to comment, edit and sign. <u>Request edit access</u>	
Ţ	(¶ ¶ +5 (+) Ø 0/5 Signature	
		Customise your Agreement ×
	Project Title	
	Diabete type II in Human DNA from ③	Project specific aim
	<u>8 comments</u>	Read more Add to MOU
	Prepared by	What is it for?
	Prepared by	lpsum dolor sit amet, consectetur adipiscing elit.
	Who is compilling this agreement	When to use it?
	8 comments	Odio dictumst tempus magna elit cras posuere cursus pulvinar id. Facilisis at eu amet ornare enim arcu malesuada rutrum a.
	Prepared by	
	Margaret Leblanc Sohn Koffi	Proposed research output
	Who is compilling this agreement	Read more Remove
	Proposed Research Output	What is it for?
	Enter a description	Ipsum dolor sit amet, consectetur adipiscing elit.
	Enter a description	When to use it?
		Odio dictumst tempus magna elit cras posuere cursus pulvinar id. Facilisis at eu amet ornare enim arcu malesuada rutrum a.
	Max 500 characters	Intellectual property owner
	Intellectual Property Owner	Read more Remove
		What is it for?
	Who the intellectual property for this project resides with	Ipsum dolor sit amet, consectetur adipiscing elit.
		When to use it?
	Ethics Considerations	Odio dictumst tempus magna elit cras posuere
	ج	cursus pulvinar id. Facilisis at eu amet ornare enim arcu malesuada rutrum a.
	Cilck to upload or drag and drop SVG, PNG, JPG or GIF (max. 800×400px)	Ethics considerations
		Read more Remove
	Send	What is it for?
		Ipsum dolor sit amet, consectetur adipiscing elit.

Build a data- or biospecimen-sharing agreement

- Elements to create a customised data- or biospecimen-sharing agreement.
- Invite institutional representatives
- Negotiate benefit sharing
- Build a benefit sharing agreement
 - (Dr) Tsaone Tamuhla



÷		Customise Sign Agree
Da	ata Sharing Agreement	
You	are able to comment, edit and sign. <u>Request edit access</u>	
()	🕵 🕼 +5 🕂 🔊 0/5 Signature	
	Project Title	Customise your Agreement
	Diabete type II in Human DNA from	Project specific aim
	8 comments	Read more Add to MOU
	Prepared by	What is it for?
	Margaret Leblanc S John Koffi	lpsum dolor sit amet, consectetur adipiscing elit.
	Who is compilling this agreement	When to use it?
	<u>8 comments</u>	Odio dictumst tempus magna elit cras posuere cursus pulvinar id. Facilisis at eu amet ornare eni arcu malesuada rutrum a.
	Prepared by	
	Margaret Leblanc Sohn Koffi	Proposed research output
	Who is compilling this agreement	Read more Remove
::	Proposed Research Output	What is it for?
	Enter a description	Ipsum dolor sit amet, consectetur adipiscing elit.
		When to use it?
		Odio dictumst tempus magna elit cras posuere cursus pulvinar id. Facilisis at eu amet ornare eni arcu malesuada rutrum a.
	Max 500 characters	Intellectual property owner
H	Intellectual Property Owner	Read more Remove
		What is it for?
	Who the intellectual property for this project resides with	lpsum dolor sit amet, consectetur adipiscing elit.
		When to use it?
	Ethics Considerations	Odio dictumst tempus magna elit cras posuere
		cursus pulvinar id. Facilisis at eu amet ornare eni arcu malesuada rutrum a.
	Click to upload or drag and drop SVG, PNG, JPG or GIF (max. 800×400px)	Ethics considerations
		Read more Remove
	Send	What is it for?

Progress to date

End of 2022 Completed detailed specification:

Front end design – Hominum Global team

- User interface design and functionality, wireframing
- Metadata structure
- Detailed metadata structure with ontologies for human and microbial data
- Search term functionality
- User testing

Back end specification – MethodLab team

- Containerised (docker), can be redeployed and shared when complete
- SQL Relational database, ease of admin and maintenance
- Optimised for restricted internet bandwidth (loaded to user end for search)
- Ilifu local cloud server infrastructure: <u>www.ilifu.ac.za</u>



Next steps

Platform development – MethodLab team

- Started 1 June 2023
- 18 month timeline

First stakeholder workshop

- Entebbe, Uganda 10 12 July 2023
- Focus group genomics researchers
- Open day at MRC Uganda/LSHTM co-hosted with Dr Segun Fatumo



Acknowledgements







African Data and Biospecimen Exchange Made possible by a Calestous Juma Fellowship (N Tiffin) awarded by the **Bill & Melinda Gates Foundation**

Hominum Global

User interface and platform development Nicol Ronga and Maria Cavanna <u>https://hominum.global/</u> Cape Town

MethodLab Platform Software Development Tim Smith and Brendon Joseph info@methodlab.io

Cape Town



Also recognising funding from: UKRI/MRC UK (MC_PC_22007)